Document is current
Any future updates will be listed below
-
Authors
Liu, Clarissa M.
Killion, Elizabeth A. https://orcid.org/0000-0002-9321-3886
Hammoud, Rola https://orcid.org/0009-0003-7184-1050
Lu, Shu-Chen
Komorowski, Renee
Liu, Tongyu
Kanke, Matt
Thomas, Veena A. https://orcid.org/0000-0002-5202-6697
Cook, Kevin https://orcid.org/0000-0003-3079-4174
Sivits, Glenn N. Jr. https://orcid.org/0000-0002-9621-5449
Ben, Aerielle B.
Atangan, Larissa I.
Hussien, Rajaa
Tang, Amy https://orcid.org/0009-0001-6548-905X
Shkumatov, Artem
Li, Chi-Ming https://orcid.org/0000-0002-2740-5652
Drucker, Daniel J. https://orcid.org/0000-0001-6688-8127
Véniant, Murielle M. https://orcid.org/0000-0002-1881-8252
-
Funding
Funding for this research was provided by:
Amgen
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (154321)
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (154321)
- License Information
-
More Information
Article History
Received: 16 October 2024
Accepted: 28 March 2025
First Online: 29 April 2025
Competing interests
: All authors, with the exception of D.J.D. and R.H., are or were employees or contractors of Amgen and have received Amgen stock. Most of the work has been included in patent no. PCT/US2016/068138: ‘Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists.’ D.J.D. has served as a consultant or speaker within the past 12 months to Amgen, AstraZeneca, Insulet, Kallyope, Novo Nordisk and Pfizer. D.J.D. holds non-exercised options in Kallyope.
